Limits...
Trends in Malignant Glioma Monoclonal Antibody Therapy

View Article: PubMed Central

ABSTRACT

Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major clinical trials and possible therapeutic combinations of bevacizumab, the most common monoclonal antibody to vascular endothelial growth factor (VEGF). Another humanized antibody to gain recognition in GBM is epidermal growth factor (EGFR) antagonist nimotuzumab. Other antigens (VEGF receptor, platelet-derived growth factor receptor, hepatocyte growth factor and c-Met system) showed significance in gliomas and were used to create monoclonal antibodies applied in different malignant tumors. We assess the role of genetic markers (isocitrate dehydrogenase, O6-methylguanine-DNA methyltransnsferase) in GBM treatment outcome prediction. Besides antibodies studied in clinical trials, we focus on perspective targets and briefly list other means of passive immunotherapy.

No MeSH data available.


Related in: MedlinePlus

OS and PFS dependence on MGMT methylation status in monoclonal antibody + radiotherapy + temozolomide vs. placebo + radiotherapy + temozolomide trials. In Lai et al. (2011) study [47], PFS control for unmethylated MGMT tumors data were not provided. In Westphal et al. study (2015) [84], median OS in methylated MGMT tumors in treatment group was not reached. In Gilbert et al. (2014) [50], favorable and unfavorable genetic profiles were made up on the basis of a genetic essay and are not discussed here. The “n” reflects the number of patients with MGMT promoter methlylation status data, except the data of RTOG 0825 study, where the total number of favorable and unfavorable genetic profile patients is shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4997917&req=5

Figure 2: OS and PFS dependence on MGMT methylation status in monoclonal antibody + radiotherapy + temozolomide vs. placebo + radiotherapy + temozolomide trials. In Lai et al. (2011) study [47], PFS control for unmethylated MGMT tumors data were not provided. In Westphal et al. study (2015) [84], median OS in methylated MGMT tumors in treatment group was not reached. In Gilbert et al. (2014) [50], favorable and unfavorable genetic profiles were made up on the basis of a genetic essay and are not discussed here. The “n” reflects the number of patients with MGMT promoter methlylation status data, except the data of RTOG 0825 study, where the total number of favorable and unfavorable genetic profile patients is shown.


Trends in Malignant Glioma Monoclonal Antibody Therapy
OS and PFS dependence on MGMT methylation status in monoclonal antibody + radiotherapy + temozolomide vs. placebo + radiotherapy + temozolomide trials. In Lai et al. (2011) study [47], PFS control for unmethylated MGMT tumors data were not provided. In Westphal et al. study (2015) [84], median OS in methylated MGMT tumors in treatment group was not reached. In Gilbert et al. (2014) [50], favorable and unfavorable genetic profiles were made up on the basis of a genetic essay and are not discussed here. The “n” reflects the number of patients with MGMT promoter methlylation status data, except the data of RTOG 0825 study, where the total number of favorable and unfavorable genetic profile patients is shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4997917&req=5

Figure 2: OS and PFS dependence on MGMT methylation status in monoclonal antibody + radiotherapy + temozolomide vs. placebo + radiotherapy + temozolomide trials. In Lai et al. (2011) study [47], PFS control for unmethylated MGMT tumors data were not provided. In Westphal et al. study (2015) [84], median OS in methylated MGMT tumors in treatment group was not reached. In Gilbert et al. (2014) [50], favorable and unfavorable genetic profiles were made up on the basis of a genetic essay and are not discussed here. The “n” reflects the number of patients with MGMT promoter methlylation status data, except the data of RTOG 0825 study, where the total number of favorable and unfavorable genetic profile patients is shown.

View Article: PubMed Central

ABSTRACT

Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major clinical trials and possible therapeutic combinations of bevacizumab, the most common monoclonal antibody to vascular endothelial growth factor (VEGF). Another humanized antibody to gain recognition in GBM is epidermal growth factor (EGFR) antagonist nimotuzumab. Other antigens (VEGF receptor, platelet-derived growth factor receptor, hepatocyte growth factor and c-Met system) showed significance in gliomas and were used to create monoclonal antibodies applied in different malignant tumors. We assess the role of genetic markers (isocitrate dehydrogenase, O6-methylguanine-DNA methyltransnsferase) in GBM treatment outcome prediction. Besides antibodies studied in clinical trials, we focus on perspective targets and briefly list other means of passive immunotherapy.

No MeSH data available.


Related in: MedlinePlus